Science Corporation announced Thursday that the company raised $230 million as it awaits a decision from the Food and Drug Administration on PRIMA, its wireless retinal implant.
The Series C funding round includes investors from Lightspeed Venture Partners, Khosla Ventures, Y Combinator, Quiet Capital, and IQT, the investor arm for the CIA and the broader U.S. intelligence community. The company has raised roughly $490 million since Max Hodak founded the startup in 2021.
The company expects to launch its device later this year in Europe after clinical trial results showed that the system — which pairs glasses that project near-infrared light with the retinal implant — restored central vision and improved visual acuity in people with late-stage macular degeneration after 12 months.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.